Beckman Coulter

The firm beat the consensus Wall Street estimates on the top and bottom lines as the diagnostics segment saw revenues grow 20 percent year over year. 

A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.

Overall growth was driven by the company's diagnostics segment, which rose 11 percent, while life sciences improved 6 percent

The deal gives Beckman Coulter non-exclusive distribution rights in the US and Canada to the NGS library preparation kits for cell-free DNA in plasma.

The Beckman Coulter unit provides genomic sequencing solutions to healthcare businesses, governments, and academia around the world.

IncellDx's investigational molecular assay used to quantify HPV E6/E7 mRNA in single cells has been optimized to run on Beckman Coulter's CytoFlex flow cytometry system.

Following a beta evaluation of the system, a virology lab in Sheffield, UK, ran a workflow assessment and found improvements with the system.

The DxN Veris was recently launched as a CE-marked product with a menu of viral load tests, and will launch in a few years in the US with STD and HAI assays. 

The assays add to the test menu of Beckman Coulter's DxN Veris molecular diagnostics system.

The company lowered its full-year 2015 adjusted EPS estimate on anticipated tougher currency effects.

Pages

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.